Roche warned
about Fuzeon claims

The Food and Drug Administration has sent a letter to drugmaker Roche warning that it must immediately stop referring to its HIV fusion inhibitor, Fuzeon, as having "100% antiviral activity," The Wall Street Journal reports. The FDA says a salesperson for the company made the claim during a medical conference in Washington, D.C. Roche was ordered to stop making the claim that Fuzeon is 100% effective and to stop disseminating or using educational or marketing materials that might have been used by the salesperson who made the initial claim. FDA officials say studies have shown 46% of HIV patients have some response to the drug, not the 100% the Roche salesperson claimed.